Thomas Clozel, Owkin | What does AI Biotech really mean | E10
Listen now
Description
In an online special, we’re interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents. 💎 ABOUT THE SPEAKER Thomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasn’t sure where it would go. Now it’s a unicorn following a $180M investment from Sanofi in 2021 and has over 300 employees. 🔗 LINKS MENTIONED - Exscientia Expands Biologics Design Capability with Automated Laboratory https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Expands-Biologics-Design-Capability-with-Automated-Laboratory/default.aspx - Marc de Garidel, Abivax | How to make two billion 💶 exits (kind of smoothly) | E09 https://youtu.be/njZR8udGBTQ - How AI Can Tackle Cancer - Leader in Innovation (Fast Company) https://open.spotify.com/episode/2LQGtAaD7ALSsHslNZJ1mC?si=96a0ba9ddafd4fbc - Aviv Regev leads Genentech's next revolution with AI - https://endpts.com/aviv-regev-leads-genentechs-next-revolution-with-ai/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-clozel-ai-biotech/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:26] You need a good pipeline [00:09:24] How Owkin is scaling AI in biotech [00:16:46] Augmenting AI in biotech [00:23:05] How AI can work for small/medium biotech companies [00:27:18] Always looking for more data [00:33:58] Anonymization of data and federated learning [00:42:18] Becoming a biotech company [00:47:29] Small molecules [00:49:10] Limitations [00:51:51] Growing up with billionaire biotech parents [00:56:37] Becoming unfocused and having fun [01:09:02] Getting the best investors [01:18:51] Thanks for listening
More Episodes
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and...
Published 10/28/24
Published 10/28/24